EGFR pharmacogenomics: the story continues to mutate and evolve

Am J Pharmacogenomics. 2005;5(2):137-9. doi: 10.2165/00129785-200505020-00007.
No abstract available

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Clinical Trials, Phase III as Topic
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Mutation*
  • Pharmacogenetics / trends*
  • Protein-Tyrosine Kinases / therapeutic use*
  • Quinazolines / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Quinazolines
  • CL 387785
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib